Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Nicolò M. Agnelli
Observed names:
Agnelli, Nicolò M.,
N Agnelli
Institutions:
Mario Negri Institute for Pharmacological Research,
Guglielmo da Saliceto Hospital,
Ospedale San Luigi Gonzaga
Observed institutions:
Mario Negri Institute for Pharmacological Research,
Guglielmo da Saliceto Hospital,
Ospedale San Luigi Gonzaga
ORCID:
0000-0003-2564-4286
Observed ORCID:
0000-0003-2564-4286
OpenAlex ID:
A5054357544
Safety and efficacy of propranolol for treatment of familial cerebral cavernous malformations (Treat_CCM): a randomised, open-label, blinded-endpoint, phase 2 pilot trial
2022
·
Silvia Lanfranconi
, Elisa Scola
, et al.
·
The Lancet Neurology
·
78
PDF
Higher levels of IgA and IgG at sepsis onset are associated with higher mortality: results from the Albumin Italian Outcome Sepsis (ALBIOS) trial
2021
·
Laura Alagna
, Jennifer M. T. A. Meessen
, et al.
·
Annals of Intensive Care
·
24
PDF
Circulating biomarkers in familial cerebral cavernous malformation
2023
·
Francesca Lazzaroni
, Jennifer M.T.A. Meessen
, et al.
·
EBioMedicine
·
23
P252 the Treatment With Beta–blockers After Myocardial Infarction Without Reduced Ejection Fraction (reboot) Trial, 2023 Updates
2023
·
M Bianco
, M Lazzero
, et al.
·
European Heart Journal Supplements
PDF
Show more works
View as search
Works count:
6
Citation count:
125
H-index:
3
I10-index:
3
Year
Topic
Type